Tlando (Testosterone Undecanoate) Patent Expiration, LOE Window & CMS Spending

Tlando (Testosterone Undecanoate) by Verity: FDA Orange Book LOE 2041-04-28, 0 AB generics, $872K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVerity
FDA Application & PathwayN208088 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-04-28
Orange Book Patents (*PED Extensions)15 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$872K
2024 Medicare Part D Spend$671K
2024 Medicaid Spend$201K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 29.2% 2-yr change)